RCKT vs. KROS, DCPH, ARDX, AMPH, AMRX, MRVI, EWTX, SNDX, NAMS, and DYN
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Keros Therapeutics (KROS), Deciphera Pharmaceuticals (DCPH), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), Amneal Pharmaceuticals (AMRX), Maravai LifeSciences (MRVI), Edgewise Therapeutics (EWTX), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
Keros Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals received 331 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 72.18% of users gave Rocket Pharmaceuticals an outperform vote while only 66.67% of users gave Keros Therapeutics an outperform vote.
Rocket Pharmaceuticals has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Rocket Pharmaceuticals currently has a consensus price target of $52.13, suggesting a potential upside of 130.44%. Keros Therapeutics has a consensus price target of $86.00, suggesting a potential upside of 64.50%. Given Rocket Pharmaceuticals' higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Keros Therapeutics.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 31.1% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Keros Therapeutics' return on equity of -45.53% beat Rocket Pharmaceuticals' return on equity.
In the previous week, Keros Therapeutics had 9 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 10 mentions for Keros Therapeutics and 1 mentions for Rocket Pharmaceuticals. Keros Therapeutics' average media sentiment score of 0.35 beat Rocket Pharmaceuticals' score of 0.05 indicating that Keros Therapeutics is being referred to more favorably in the news media.
Summary
Rocket Pharmaceuticals and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
